bioAffinity Announces Approximately $4 Million Registered Direct Offering of Common Stock and Concurrent Private Placement Priced At-The-Market
bioAffinity Technologies (NASDAQ: BIAF) entered a definitive agreement with an institutional investor to sell shares of common stock (or pre-funded warrants in lieu thereof) at $6.122 per share ($6.115 per pre-funded warrant) in a registered direct offering priced at-the-market under Nasdaq rules, plus a concurrent private placement of warrants to purchase up to 980,072 shares at $6.122 per share. Gross proceeds are expected to be approximately $4 million before placement agent fees and other expenses, with clos...
Key takeaways
Registered direct offering of common stock (or pre-funded warrants in lieu) priced at $6.122 per share ($6.115 per pre-funded warrant).
Concurrent private placement of warrants for up to 980,072 underlying shares at an exercise price of $6.122 per share.
Pre-funded warrants have an exercise price of $0.007 per share; common stock warrants expire five years from stockholder approval.
Gross proceeds of approximately $4 million before placement agent fees and offering expenses.
Closing expected on or about October 9, 2026, subject to customary closing conditions.
WallachBeth Capital, LLC acting as sole placement agent.
Use of proceeds: working capital, support expected growing sales for CyPath Lung, and general corporate purposes.
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow BIAF in real time
Get material earnings, filing, IR, and earnings-call alerts by email.